Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
- Chronic kidney disease (CKD) affects 850 million people worldwide,1 47 million in the EU,2 doubles a person’s risk for hospitalization,3 and is a leading cause of death2 - Jardiance® (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically

